中国肺癌骨转移临床诊疗指南(2024版)

Chinese clinical guidelines on diagnosis and treatment of lung cancer bone metastasis(version 2024)

肺癌居中国恶性肿瘤发病之首,骨转移是肺癌常见转移部位之一。随着影像学和核医学技术不断进步,骨转移早诊水平均有所提高。针对肺癌骨转移全身系统治疗(化疗、靶向治疗、免疫治疗)以及骨改良药已有更多循证依据和进展。多学科(肿瘤内科、外科、放疗、介入、核素、心理康复等)指导下的综合治疗模式已经日趋成熟。鉴于此,中国医药教育协会肺癌医学教育委员会、北京医学奖励基金会肺癌青年专家委员会、中国老年保健协会肺癌专业委员会在《肺癌骨转移诊疗专家共识(2019版)》的基础上,制定了《中国肺癌骨转移临床诊疗指南(2024版)》,旨在提升我国肺癌骨转移的综合治疗水平。

Lung cancer is the highest morbidity of malignant tumor in China,and bone metastasis is one of the common sites.With the development of imaging and nuclear medicine technology,the level of early diagnosis of bone metastasis has been improved.There are also many evidence-based evidences and advances in systemic therapy(chemotherapy,targeted therapy,immunotherapy)and bone modification drugs for treatment of bone metastases from lung cancer.The comprehensive treatment model under the guidance of multiple disciplines(including medical oncology,surgery,radiotherapy,interventional medicine,nuclear medicine,psychological rehabilitation,etc.)has been widely implemented in clinical practice.Therefore,Lung Cancer Medical Education Committee of China Medicine Education Association,Youth Specialists Committee of Lung Cancer,Beijing Medical Award Foundation and Lung Cancer Specialty Committee of Chinese Elderly Health Care Association have written the"Chinese Clinical Guidelines on Diagnosis and Treatment of Lung Cancer Bone Metastasis(Version 2024)",based on the"Expert Consensus on Diagnosis and Treatment of Lung Cancer Bone Metastasis(Version 2019)".The aim is to enhance the comprehensive treatment level of lung cancer bone metastasis in China.